Mr. Vitulli's vast experience includes his current position as Chairman of Efficas, Inc., a venture backed leading developer and marketer of natural bioactive compounds utilized for nutritional management of health and wellness in humans and animals. The Efficas scientific platform and expertise focus on the immune system and the tools required in identifying, investigating and assessing effects of bioactives on immune function. Mr. Vitulli spent the first 16 years of his career at the Quaker Oats Company, most recently as President of the North American Gatorade business, one of the premier functional food products in the world.
Mr. Vitulli stated: "I believe Health Enhancement's Products' ProAlgaZyme(TM) represents a break-through technology which will have several health and wellness applications. My goal is to help the team continue its rigorous scientific study while simultaneously developing the business strategy to successfully position ProAlgaZyme as a safe and effective way to address multiple chronic conditions."
To view Mr. Vitulli's complete resume go to: http://www.heponline.com/PVitulliCV-May2009PDF.pdf
About Health Enhancement Products, Inc.
Health Enhancement Products, Inc. is an innovative health and wellness company engaged in the development of dietary supplements, food additives and ingredients using only pure, all-natural compounds. The Company's premier product is ProAlgaZyme (PAZ), a liquid product drawn from living algae grown in purified water. The water in which the algae is grown is drawn off, filtered and bottled as ProAlgaZyme.
Safe Harbor Statement
Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.

